Russell C Dale1, Margherita Nosadini1. 1. Neuroimmunology Group (R.C.D.), Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, University of Sydney, Australia; and the Paediatric Neurology and Neurophysiology Unit (M.N.), Department of Women's and Children's Health, University Hospital of Padua, Italy.
The recent paradigm that autoimmune encephalitis is associated with autoantibodies that bind to conformational epitopes of cell surface antigens involved in neurotransmission has transformed the field of autoimmune neurology and created new biomarkers for the clinician to define treatable acquired neurologic conditions. In parallel, a growing armamentarium of immune therapeutic agents is becoming available. But fundamental questions remain, particularly “why does this happen?” There is cohort-derived evidence suggesting age and ethnic vulnerability and emerging evidence of HLA associations.[1,2] Anti–NMDA receptor (NMDAR) encephalitis, which is defined by a characteristic clinical syndrome and the presence of CSF autoantibodies to the NR1 subunit of the NMDAR, is the most common autoimmune encephalitis. In anti-NMDARencephalitis, many female adults have an ovarian teratoma that contains NMDAR-expressing neural tissue, providing a hypothetical example of “cross-reactive” autoimmunity between the NMDARs in the tumor and in the brain. However, large cohorts have shown that ovarian teratomas are very uncommon in pediatric patients,[3] so what is the “trigger” of the loss of immune tolerance in young children? Some of these children have preceding herpes simplex type 1 (HSV1) encephalitis, a destructive highly inflammatory encephalitis that predominantly affects temporal lobes and surrounding structures. After recovery, approximately 20% of children with HSV1 encephalitis deteriorate with a “second phase” of encephalitis, this time with clinical features typical of anti-NMDARencephalitis, including florid movement disorders and encephalopathy, associated with the emergence of anti-NMDAR antibodies.[4-6] This clear example of HSV1 encephalitis inducing secondary anti-NMDARencephalitis yielded the hypothesis that the inflammatory destruction of neural tissue with release of neural antigens into the surrounding brain, circulation and then lymphatic system, resulted in a reactivation of autoreactive lymphocytes against NMDAR antigens and production of pathogenic anti-NMDAR antibodies.However a new article, in this month's Neurology® Neuroimmunology and Neuroinflammation, strengthens the evidence for the alternative pathophysiologic mechanism between HSV1 and anti-NMDAR autoimmunity: namely that HSV1 infection increases the likelihood of developing anti-NMDARencephalitis, possibly through “molecular mimicry,” without the need for brain tissue destruction (i.e., without HSV1 encephalitis).[7] Salovin et al. performed testing for previous HSV1 infection (immunoglobulin G [IgG] serology) in stored serum samples from children with anti-NMDARencephalitis (with typical clinical features and positive serum anti-NMDAR antibodies) with no clinical or radiologic evidence of HSV1 encephalitis. There were 2 cohorts, the first from Philadelphia and the second from Barcelona (combined mean age 9 years, range 1–17). They found statistically significant elevation of HSV1 IgG seropositivity in patients with anti-NMDARencephalitis compared with controls in the Philadelphia cohort and the combined cohorts (49% vs 21% in the combined cohorts, p = 0.007). It is important that they used hospital controls who were children with other neuroinflammatory disorders, which reduced the likelihood that the findings were due to nonspecific inflammatory associations and makes it more likely to be specific to anti-NMDARencephalitis. Second, they ensured that patients did not have IV immunoglobulin (IVIG) before serologic sampling, as IVIG may induce false-positive infectious serologic findings, given the polyclonal multidonor origins. Third, the patients were age matched with controls—this is very important, particularly with an extremely common infection such as HSV1, which has increasing seropositivity with increasing childhood age. As expected, the Barcelona control group, who were older, had higher HSV1 seropositivity. Fourth, the authors also measured IgG against 2 other very common viral infections in childhood, namely cytomegalovirus and Epstein-Barr virus, and found no difference between anti-NMDARencephalitispatients and controls.There were some weaknesses in this approach, partly related to the retrospective nature of the study. First, it would have been of interest to better understand the relationship of the timing of infection and production of anti-NMDAR antibodies, which could have been performed by measuring HSV1 IgM antibodies, and convalescent HSV1 IgG sampling. Similarly, there is no reporting of the time between onset of anti-NMDARencephalitis and serum sampling or of the type and timing of preceding clinical HSV1 infection. Second, and acknowledged by the authors, there was no controlling for race or socioeconomic factors, which may influence HSV1 infection, as the presence of other children in the family, and housing overcrowding can influence the prevalence of common childhood infectious disease. Third, it is still plausible that HSV1 could induce a subclinical HSV1 encephalitis in some patients, which could be missed clinically or radiologically—proving HSV1 PCR negativity in CSF would have added to this study and strengthened the findings further. Indeed, the detection of “asymptomatic” positive CSF PCR for HSV1 in anti-NMDARencephalitispatients has been reported and discussed in a recent review.[6] Moreover, the number of patients in the Salovin study who fulfilled Graus et al[8] clinical criteria for anti-NMDARencephalitis is unclear. It is also unclear whether NMDAR antibodies were present in CSF (or only serum). Finally, although cytomegalovirus and Epstein-Barr virus testing helped understand the specificity of the HSV1 findings, testing for other infections, particularly Mycoplasma pneumoniae would have added to the study, as Mycoplasma has been proposed to trigger anti-NMDARencephalitis,[9] and other types of herpes viruses beside HSV1 have been reported in anti-NMDARencephalitis.[6]Regardless of these limitations, the article by Salovin et al. is important and redresses the balance in the debate about induction of anti-NMDAR autoimmunity and supports the hypothesis that preceding viral infection can result in loss of immune tolerance in predisposed individuals.
Authors: Shekeeb S Mohammad; Kate Sinclair; Sekhar Pillai; Vera Merheb; Tim D Aumann; Deepak Gill; Russell C Dale; Fabienne Brilot Journal: Mov Disord Date: 2013-10-01 Impact factor: 10.338
Authors: Stefanie H Mueller; Anna Färber; Harald Prüss; Nico Melzer; Kristin S Golombeck; Tania Kümpfel; Franziska Thaler; Martin Elisak; Jan Lewerenz; Max Kaufmann; Kurt-Wolfram Sühs; Marius Ringelstein; Christoph Kellinghaus; Christian G Bien; Andrea Kraft; Uwe K Zettl; Sven Ehrlich; Robert Handreka; Kevin Rostásy; Florian Then Bergh; Jürgen H Faiss; Wolfgang Lieb; Andre Franke; Gregor Kuhlenbäumer; Klaus-Peter Wandinger; Frank Leypoldt Journal: Ann Neurol Date: 2018-04 Impact factor: 10.422
Authors: Hannah F Jones; Shekeeb S Mohammad; Peter W Reed; Paul P J Dunn; Richard H Steele; Russell C Dale; Cynthia Sharpe Journal: Dev Med Child Neurol Date: 2017-03-22 Impact factor: 5.449
Authors: Margherita Nosadini; Shekeeb S Mohammad; Francesco Corazza; Ezia Maria Ruga; Kavitha Kothur; Giorgio Perilongo; Anna Chiara Frigo; Irene Toldo; Russell C Dale; Stefano Sartori Journal: Dev Med Child Neurol Date: 2017-04-25 Impact factor: 5.449
Authors: Nicole R Florance; Rebecca L Davis; Christopher Lam; Christina Szperka; Lei Zhou; Saba Ahmad; Cynthia J Campen; Heather Moss; Nadja Peter; Amy J Gleichman; Carol A Glaser; David R Lynch; Myrna R Rosenfeld; Josep Dalmau Journal: Ann Neurol Date: 2009-07 Impact factor: 10.422
Authors: Amy Salovin; Jason Glanzman; Kylie Roslin; Thais Armangue; David R Lynch; Jessica A Panzer Journal: Neurol Neuroimmunol Neuroinflamm Date: 2018-04-05
Authors: Francesc Graus; Maarten J Titulaer; Ramani Balu; Susanne Benseler; Christian G Bien; Tania Cellucci; Irene Cortese; Russell C Dale; Jeffrey M Gelfand; Michael Geschwind; Carol A Glaser; Jerome Honnorat; Romana Höftberger; Takahiro Iizuka; Sarosh R Irani; Eric Lancaster; Frank Leypoldt; Harald Prüss; Alexander Rae-Grant; Markus Reindl; Myrna R Rosenfeld; Kevin Rostásy; Albert Saiz; Arun Venkatesan; Angela Vincent; Klaus-Peter Wandinger; Patrick Waters; Josep Dalmau Journal: Lancet Neurol Date: 2016-02-20 Impact factor: 44.182
Authors: Karol Perlejewski; Agnieszka Pawełczyk; Iwona Bukowska-Ośko; Małgorzata Rydzanicz; Tomasz Dzieciątkowski; Marcin Paciorek; Michał Makowiecki; Kamila Caraballo Cortés; Marta Grochowska; Marek Radkowski; Tomasz Laskus Journal: Open Forum Infect Dis Date: 2020-10-07 Impact factor: 3.835
Authors: João Moura; Sara Duarte; Ana Sardoeira; João Neves-Maia; Joana Damásio; Ricardo Taipa; Paula Carneiro; Esmeralda Neves; Ana Campar; Ernestina Santos Journal: Neurohospitalist Date: 2022-04